9月14日，药明生物盘中上涨3.06%，报48.44港元/股，成交额3.45亿港元。同日生命科学工具和服务板块集体走强，康龙化成涨5.74%，药明康德涨3.23%，金斯瑞生物科技涨2.35%。
消息面上，近期CXO及创新药板块迎来估值修复行情，多家券商确认板块底部特征，"药明系"企业此前推出合计最高约55亿元回购计划对股价形成提振。公司层面，上半年收益117.87亿元，同比增长18.4%，经调整归母净利同比增长38.4%，全年业绩指引上调；未完成订单约55亿美元，同比增长约30%。此外，华创证券近日给予增持评级，目标价66.23港元，大摩亦将目标价升至57港元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.